ICER reviewing drugs for relapsing-remitting multiple sclerosis
The US not-for-profit organization the Institute for Clinical and Economic Review (ICER) has posted a draft scoping document which will inform a report on drug therapies for treatment of relapsing-remitting multiple sclerosis (RRMS).
The document was developed with input from key stakeholders, including relevant patient organizations, clinical experts, and manufacturers of the drugs under study. The document will be open to public comment for two weeks, until July 15. The scoping document will inform the development of a report evaluating the comparative clinical effectiveness and value of drug therapies for RRMS. The drugs to be reviewed in the report include:
- Platform agents: interferon beta-1a, peginterferon beta-1a, interferon beta-1b, glatiramer acetate
- Stakeholders indicated greatest interest in a comparison of Avonex(from Biogen [Nasdaq: BIIB]) and Rebif (EMD Serono, a unit of Merck KGaA [MRK: DE]), two competing formulations of interferon beta-1a. As a result, ICER will perform a detailed comparison of the two agents and will summarize the existing literature on other platform agents.
- Oral agents:
- dimethyl fumarate (Tecfidera, from Biogen)
- fingolimod (Gilenya, from Novartis [NOVN: VX]),
- teriflunomide (Aubagio, Sanofi [Euronext: SAN])
- Other injectable or infused MS agents:
- alemtuzumab (Lemtrada, from Sanofi)
- daclizumab (Zinbryta, from Biogen and AbbVie [NYSE: ABBV])
- natalizumab (Tysabri, from Biogen)
- ocrelizumab (Ocrevus, from Roche [ROG: SIX]/Genentech)
- rituximab (Rituxan, Roche/Genentech)
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze